Financial Snapshot

Revenue
$820.0K
TTM
Gross Margin
262.73%
TTM
Net Earnings
-$7.958M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
141.99%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$22.73M
Q3 2024
Cash
Q3 2024
P/E
-13.15
Nov 29, 2024 EST
Free Cash Flow
-$36.78M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $1.924M $18.05M $5.398M $6.699M $6.750M $7.028M $27.81M $1.153M $0.00 $0.00 $0.00 $80.00K $210.0K
YoY Change -89.34% 234.4% -19.42% -0.76% -3.96% -74.73% 2312.27% -100.0% -61.9%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $1.924M $18.05M $5.398M $6.699M $6.750M $7.028M $27.81M $1.153M $0.00 $0.00 $0.00 $80.00K $210.0K
Cost Of Revenue $1.284M $3.434M $1.491M $300.0K -$566.5K $3.261M $635.6K $0.00 $0.00
Gross Profit $640.0K $14.62M $3.907M $6.399M $7.317M $3.768M $27.18M $1.153M $0.00
Gross Profit Margin 33.26% 80.98% 72.38% 95.52% 108.39% 53.61% 97.71% 100.0%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Selling, General & Admin $10.30M $20.71M $24.66M $19.76M $11.61M $11.06M $8.511M $7.083M $4.423M $4.880M $4.020M $2.100M $840.0K
YoY Change -50.27% -16.01% 24.79% 70.23% 4.98% 29.9% 20.16% 60.15% -9.37% 21.39% 91.43% 150.0%
% of Gross Profit 1609.38% 141.69% 631.12% 308.78% 158.64% 293.45% 31.32% 614.33%
Research & Development $13.78M $31.31M $59.84M $32.19M $11.76M $5.787M $4.373M $10.15M $6.587M $12.24M $8.910M $8.480M $2.820M
YoY Change -55.97% -47.68% 85.86% 173.65% 103.3% 32.34% -56.92% 54.09% -46.19% 37.38% 5.07% 200.71%
% of Gross Profit 2153.75% 214.19% 1531.48% 503.09% 160.78% 153.58% 16.09% 880.31%
Depreciation & Amortization $158.0K $166.0K $1.657M $1.843M $3.884M $4.555M $425.5K $26.86K $23.51K $28.94K $20.00K $20.00K $0.00
YoY Change -4.82% -89.98% -10.09% -52.54% -14.74% 970.56% 1484.29% 14.24% -18.78% 44.72% 0.0%
% of Gross Profit 24.69% 1.14% 42.41% 28.8% 53.08% 120.89% 1.57% 2.33%
Operating Expenses $24.08M $31.31M $84.49M $51.95M $23.37M $57.64M $13.92M $17.23M $11.01M $12.24M $12.93M $10.57M $3.660M
YoY Change -23.07% -62.95% 62.64% 122.29% -59.45% 313.99% -19.21% 56.52% -10.05% -5.33% 22.33% 188.8%
Operating Profit -$23.44M -$37.44M -$82.13M -$72.84M -$16.14M -$35.38M $13.89M -$16.08M -$11.01M -$17.12M
YoY Change -37.38% -54.42% 12.75% 351.39% -54.39% -354.71% -186.38% 46.05% -35.67%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Interest Expense -$4.137M -$4.170M -$2.391M $49.00K $121.3K $16.26K -$24.02K -$464.2K -$793.2K -$1.206M -$110.0K $0.00 -$40.00K
YoY Change -0.79% 74.4% -4979.59% -59.61% 646.12% -167.71% -94.83% -41.48% -34.24% 996.53% -100.0%
% of Operating Profit -0.17%
Other Income/Expense, Net -$42.00K -$4.190M -$2.411M $5.666M $147.0K $54.93K -$53.64K -$391.6K $519.8K $1.060M
YoY Change -99.0% 73.79% -142.55% 3755.18% 167.57% -202.4% -86.3% -175.32% -50.96%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Pretax Income -$31.53M -$41.63M -$84.55M -$67.18M -$15.99M -$35.32M $13.84M -$16.47M -$10.49M -$16.06M -$13.05M -$10.49M -$3.480M
YoY Change -24.26% -50.76% 25.86% 320.1% -54.73% -355.3% -184.0% 57.02% -34.68% 23.07% 24.4% 201.44%
Income Tax $14.00K $28.00K -$196.0K -$2.793M $280.3K -$49.47K $1.967M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income 14.21%
Net Earnings -$31.54M -$41.66M -$84.40M -$63.50M -$16.07M -$40.05M $11.87M -$16.47M -$10.49M -$16.06M -$13.13M -$10.49M -$3.480M
YoY Change -24.28% -50.64% 32.91% 295.08% -59.87% -437.43% -172.06% 57.02% -34.66% 22.28% 25.17% 201.44%
Net Earnings / Revenue -1639.5% -230.78% -1563.54% -947.9% -238.1% -569.87% 42.68% -1428.6% -13112.5% -1657.14%
Basic Earnings Per Share -$114.00 -$4.43 -$1.20 $0.42 -$1.87 -$4.71
Diluted Earnings Per Share -$113.60 -$4.43 -$10.14M -$11.43M -$4.498M -$1.20 $0.42 -$1.87 -$4.71 -$4.90 -$18.25 -$14.56 -$4.84

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Cash & Short-Term Investments $7.415M $13.17M $54.59M $18.92M $11.24M $10.65M $2.472M $5.128M $21.16M $11.74M $3.420M $9.520M $1.110M
YoY Change -43.71% -75.87% 188.51% 68.35% 5.56% 330.64% -51.79% -75.77% 80.24% 243.27% -64.08% 757.66%
Cash & Equivalents $7.415M $13.17M $54.59M $18.92M $3.609M $10.65M $2.472M $5.128M $21.16M $11.74M $3.420M $9.520M $1.110M
Short-Term Investments $0.00 $7.629M $0.00
Other Short-Term Assets $844.0K $1.305M $2.423M $2.697M $1.222M $4.883M $705.2K $402.4K $460.0K $420.0K $710.0K $430.0K $110.0K
YoY Change -35.33% -46.14% -10.17% 120.73% -74.97% 592.46% 75.26% -12.53% 9.52% -40.85% 65.12% 290.91%
Inventory $0.00 $20.00K $38.00K $3.140K $21.33K $317.9K $382.2K
Prepaid Expenses
Receivables $0.00 $1.060M $2.177M $1.002M $822.3K $2.935M
Other Receivables $1.919M $3.739M $2.208M $4.241M $5.262M $4.180M
Total Short-Term Assets $8.395M $16.42M $61.85M $26.01M $17.72M $21.93M $10.67M $5.663M $21.62M $12.16M $4.140M $9.950M $1.220M
YoY Change -48.86% -73.46% 137.82% 46.72% -19.19% 105.47% 88.5% -73.81% 77.8% 193.72% -58.39% 715.57%
Property, Plant & Equipment $1.965M $2.411M $2.695M $1.607M $1.448M $586.5K $44.61K $43.24K $40.00K $40.00K $70.00K $60.00K $60.00K
YoY Change -18.5% -10.54% 67.7% 11.01% 146.83% 1214.75% 3.17% 8.1% 0.0% -42.86% 16.67% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $131.0K $131.0K $1.227M $148.6K $102.0K $29.56M $131.4K $62.83K $0.00 $120.0K $870.0K $10.00K $0.00
YoY Change 0.0% -89.32% 725.48% 45.8% -99.66% 22403.21% 109.06% -100.0% -86.21% 8600.0%
Total Long-Term Assets $12.60M $16.95M $18.37M $17.75M $18.38M $48.32M $32.13M $106.1K $40.00K $160.0K $940.0K $70.00K $70.00K
YoY Change -25.68% -7.72% 3.49% -3.45% -61.95% 50.37% 30191.04% 165.2% -75.0% -82.98% 1242.86% 0.0%
Total Assets $20.99M $33.37M $80.21M $43.76M $36.11M $70.25M $42.81M $5.769M $21.66M $12.32M $5.080M $10.02M $1.290M
YoY Change
Accounts Payable $446.0K $2.882M $3.369M $2.574M $2.078M $1.446M $1.299M $1.010M $680.0K $930.0K $1.640M $820.0K $240.0K
YoY Change -84.52% -14.46% 30.91% 23.88% 43.66% 11.33% 28.59% 48.56% -26.88% -43.29% 100.0% 241.67%
Accrued Expenses $4.172M $12.71M $16.14M $11.31M $5.565M $5.374M $6.788M $942.4K $1.890M $980.0K $990.0K $720.0K $310.0K
YoY Change -67.17% -21.3% 42.74% 103.22% 3.55% -20.83% 620.27% -50.14% 92.86% -1.01% 37.5% 132.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $3.040M
YoY Change -100.0%
Long-Term Debt Due $0.00 $5.930M $0.00 $2.354M $3.210M $1.910M $0.00
YoY Change -100.0% -100.0% -26.68% 68.06%
Total Short-Term Liabilities $4.618M $22.11M $19.89M $15.22M $12.16M $26.22M $11.09M $4.312M $5.850M $4.990M $3.070M $1.540M $3.780M
YoY Change -79.12% 11.19% 30.63% 25.2% -53.62% 136.41% 157.18% -26.29% 17.23% 62.54% 99.35% -59.26%
Long-Term Debt $0.00 $13.49M $32.83M $0.00 $0.00 $0.00 $0.00 $0.00 $2.350M $5.310M $0.00 $0.00 $0.00
YoY Change -100.0% -58.93% -100.0% -55.74%
Other Long-Term Liabilities $8.916M $8.541M $4.298M $3.878M $2.867M $23.06M $3.851M $1.250M $370.0K $0.00 $0.00
YoY Change 4.39% 98.72% 10.82% 35.28% -87.57% 498.75% 208.07% 237.84%
Total Long-Term Liabilities $8.916M $22.03M $37.13M $3.878M $2.867M $23.06M $3.851M $1.250M $2.720M $5.310M $0.00 $0.00 $0.00
YoY Change -59.52% -40.68% 857.38% 35.28% -87.57% 498.75% 208.07% -54.04% -48.78%
Total Liabilities $13.69M $44.28M $57.13M $19.19M $15.11M $49.34M $14.95M $5.562M $8.570M $10.30M $3.070M $1.540M $3.780M
YoY Change -69.09% -22.49% 197.66% 27.0% -69.37% 230.11% 168.75% -35.1% -16.8% 235.5% 99.35% -59.26%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Basic Shares Outstanding 277.7K shares 9.408M shares 34.77M shares 18.41M shares 8.830M shares 2.226M shares
Diluted Shares Outstanding 277.7K shares 9.408M shares 34.77M shares 18.75M shares 8.830M shares 2.226M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $104.64 Million

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. The company is headquartered in Rockville, Maryland and currently employs 19 full-time employees. The company went IPO on 2015-11-13. The firm's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

Industry: Pharmaceutical Preparations Peers: ABVC BIOPHARMA, INC. Spyre Therapeutics, Inc. Ainos, Inc. Neurogene Inc. Aravive, Inc. Comera Life Sciences Holdings, Inc. Marker Therapeutics, Inc. MAIA Biotechnology, Inc. ORAGENICS INC